Urotensin II: A novel target in human corpus cavernosum

Journal of Sexual Medicine

Volumn 7, Issue 5, 2010, Pages 1778-1786

  d'Emmanuele di Villa Bianca, Roberta ^a   Cirino, Giuseppe ^a   Mitidieri, Emma ^a   Coletta, Ciro ^a   Grassia, Gianluca ^a   Roviezzo, Fiorentina ^a   Grieco, Paolo ^a   Novellino, Ettore ^a   Imbimbo, Ciro ^a   Mirone, Vincenzo ^a   Sorrentino, Raffaella ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Erection Physiology; Human Corpus Cavernosum; Nitric Oxide; Rat; Urotensin II; Urotensin II Receptor

Indexed keywords

MESSENGER RNA; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; UROTENSIN II; UROTENSIN RECEPTOR; G PROTEIN COUPLED RECEPTOR; UROTENSIN; UTS2R PROTEIN, HUMAN; UTS2R PROTEIN, RAT;

ANESTHESIA; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE MEASUREMENT; CONTROLLED STUDY; CORPUS CAVERNOSUM; DRUG SYNTHESIS; DRUG TARGETING; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; INCUBATION TIME; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VASOCONSTRICTION; WESTERN BLOTTING; ANIMAL; FLUORESCENCE MICROSCOPY; GENETICS; METABOLISM; PENIS; PENIS ERECTION; PHYSIOLOGY; VASCULAR ENDOTHELIUM; WISTAR RAT;

ANIMALS; BLOTTING, WESTERN; ENDOTHELIUM, VASCULAR; HUMANS; MALE; MICROSCOPY, FLUORESCENCE; NITRIC OXIDE; PENILE ERECTION; PENIS; RATS; RATS, WISTAR; RECEPTORS, G-PROTEIN-COUPLED; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; UROTENSINS;

EID: 77953558269     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/j.1743-6109.2009.01450.x     Document Type: Article

References (43)

1. Bern HA, Pearson D, Larson BA, Nishioka RS. Neurohormones from fish tails: The caudal neurosecretory system. I. " Urophysiology" and the caudal neurosecretory system of fishes. Recent Prog Horm Res 1985, 41:533-52.
2. Conlon JM, Yano K, Waugh D, Hazon N. Distribution and molecular forms of urotensin II and its role in cardiovascular regulation in vertebrates. J Exp Zool 1996, 275:226-38.
3. Ames RS, Sarau HM, Chambers JK, Willette RN, Aiyar NV, Romanic AM, Louden CS, Foley JJ, Sauermelch CF, Coatney RW, Ao Z, Disa J, Holmes SD, Stadel JM, Martin JD, Liu WS, Glover GI, Wilson S, McNulty DE, Ellis CE, Elshourbagy NA, Shabon U, Trill JJ, Hay DW, Ohlstein EH, Bergsma DJ, Douglas SA. Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14. Nature 1999, 401:282-6.
4. Coulouarn Y, Lihrmann I, Jegou S, Anouar Y, Tostivint HC, Beauvillain J, Conlon JM, Bern HA, Vaudry H. Cloning of the cDNA encoding the urotensin II precursor in frog and human reveals intense expression of the urotensin II gene in motoneurons of the spinal cord. Proc Natl Acad Sci USA 1998, 95:15803-8.
5. Cheung BM, Leung R, Man YB, Wong LY. Plasma concentration of urotensin II is raised in hypertension. J Hypertens 2004, 22:1341-4.
6. Douglas SA, Dhanak D, Johns DG. From " gills to pills": Urotensin-II as a regulator of mammalian cardiorenal function. Trends Pharmacol Sci 2004, 25:76-85.
7. Douglas SA, Ashton DJ, Sauermelch CF, Coatney RW, Ohlstein DH, Ruffolo MR, Ohlstein EH, Aiyar NV, Willette RN. Human urotensin-II is a potent vasoactive peptide: Pharmacological characterization in the rat, mouse, dog and primate. J Cardiovasc Pharmacol 2000, 36(suppl 1):S163-6.
8. Douglas SA, Ohlstein EH. Human urotensin-II, the most potent mammalian vasoconstrictor identified to date, as a therapeutic target for the management of cardiovascular disease. Trends Cardiovasc Med 2000, 10:229-37.
9. Camarda V, Rizzi A, Calò G, Gendron G, Perron SI, Kostenis E, Zamboni P, Mascoli F, Regoli D. Effects of human urotensin II in isolated vessels of various species; comparison with other vasoactive agents. Naunyn Schmiedebergs Arch Pharmacol 2002, 365:141-9.
10. Douglas SA, Sulpizio AC, Piercy V, Sarau HM, Ames RS, Aiyar NV, Ohlstein EH, Willette RN. Differential vasoconstrictor activity of human urotensin-II in vascular tissue isolated from the rat, mouse, dog, pig, marmoset and cynomolgus monkey. Br J Pharmacol 2000, 131:1262-74.
11. MacLean MR, Alexander D, Stirrat A, Gallagher M, Douglas SA, Ohlstein EH, Morecroft I, Polland K. Contractile responses to human urotensin-II in rat and human pulmonary arteries: Effect of endothelial factors and chronic hypoxia in the rat. Br J Pharmacol 2000, 130:201-4.
12. Rossowski WJ, Cheng BL, Taylor JE, Datta R, Coy DH. Human urotensin II-induced aorta ring contractions are mediated by protein kinase. C, tyrosine kinases and Rho-kinase: Inhibition by somatostatin receptor antagonists. Eur J Pharmacol 2002, 438:159-70.
13. Bottrill FE, Douglas SA, Hiley CR, White R. Human urotensin-II is an endothelium-dependent vasodilator in rat small arteries. Br J Pharmacol 2000, 130:1865-70.
14. Stirrat A, Gallagher M, Douglas SA, Ohlstein EH, Berry C, Kirk A, Richardson M, MacLean MR. Potent vasodilator responses to human urotensin-II in human pulmonary and abdominal resistance arteries. Am J Physiol Heart Circ Physiol 2001, 280:H925-8.
15. Zhang AY, Chen YF, Zhang DX, Yi FX, Qi J, Andrade-Gordon P, de Garavilla L, Li PL, Zou AP. Urotensin II is a nitric oxide-dependent vasodilator and natriuretic peptide in the rat kidney. Am J Physiol Renal Physiol 2003, 285:F792-8.
16. Brailoiu E, Jiang X, Brailoiu GC, Yang J, Chang JK, Wang H, Dun NJ. State-dependent calcium mobilization by urotensin-II in cultured human endothelial cells. Peptides 2008, 29:721-6.
17. Affolter JT, Newby DE, Wilkinson IB, Winter MJ, Balment RJ, Webb DJ. No effect on central or peripheral blood pressure of systemic urotensin II infusion in humans. Br J Clin Pharmacol 2000, 54:617-21.
18. Abdelrahman AM, Pang CC. Involvement of the nitric oxide/L-arginine and sympathetic nervous systems on the vasodepressor action of human urotensin II in anesthetized rats. Life Sci 2002, 71:819-25.
19. Ignarro LJ, Bush PA, Buga GM, Wood KS, Fukuto JM, Rajfer J. Nitric oxide and cyclic GMP formation upon electrical field stimulation cause relaxation of corpus cavernosum smooth muscle. Biochem Biophys Res Commun 1990, 170:843-50.
20. Waldkirch E, Uckert S, Sigl K, Imkamp F, Langnaese K, Richter K, Jonas U, Sohn M, Stief C, Wolf G, Hedlund P. Expression and distribution of cyclic GMP-dependent protein kinase-1 isoforms in human penile erectile tissue. J Sex Med 2008, 5:536-43.
21. Ganz P. Erectile dysfunction: Pathophysiologic mechanisms pointing to underlying cardiovascular disease. Am J Cardiol 2005, 96:8M-12M.
22. Hodges LD, Kirby M, Solanki J, O'Donnell J, Brodie DA. The temporal relationship between erectile dysfunction and cardiovascular disease. Int J Clin Pract 2007, 61:2019-25.
23. Mirone V, Sorrentino R, di Villa Bianca R, Imbimbo C, Palmieri A, Fusco F, Tajana G, Cirino G. A standardized procedure for using human corpus cavernosum strips to evaluate drug activity. J Pharmacol Toxicol Methods 2000, 44:477-82.
24. Grieco P, Carotenuto A, Campiglia P, Zampelli E, Patacchini R, Maggi CA, Novellino E, Rovero P. A new, potent urotensin II receptor peptide agonist containing a Pen residue at the disulfide bridge. J Med Chem 2000, 45:4391-4.
25. d'Emmanuele di Villa Bianca R, Sorrentino R, Maffia P, Mirone V, Imbimbo C, Fusco F, De Palma R, Ignarro LJ, Cirino G. Hydrogen sulfide as a mediator of human corpus cavernosum smooth-muscle relaxation. Proc Natl Acad Sci USA 2009, 106:4513-8.
26. Pearson D, Shively JE, Clark BR, Geschwind II, Barkley M, Nishioka RS, Bern HA. Urotensin II: A somatostatin-like peptide in the caudal neurosecretory system of fish. Proc Natl Acad Sci 1980, 77:5021-4.
27. Balment RJ, Song W, Ashton N. Urotensin II: Ancient hormone with new functions in vertebrate body fluid regulation. Ann N Y Acad Sci 2005, 1040:66-73.
28. Maguire JJ, Kuc RE, Davenport AP. Orphan-receptor ligand human urotensin II: Receptor localization in human tissues and comparison of vasoconstrictor responses with endothelin-1. Br J Pharmacol 2000, 131:441-6.
29. Gibson A. Complex effects of Gillichthys urotensin II on rat aortic strips. Br J Pharmacol 1987, 91:205-12.
30. Gendron G, Gobeil F, Bélanger S, Gagnon S, Regoli D, D'Orléans-Juste P. Urotensin II-induced hypotensive responses in Wistar-Kyoto (Wky) and spontaneously hypertensive (Shr) rats. Peptides 2005, 26:1468-74.
31. Gruson D, Rousseau MF, Ahn SA, van Linden F, Ketelslegers JM. Circulating urotensin II levels in moderate to severe congestive heart failure: Its relations with myocardial function and well established neurohormonal markers. Peptides 2006, 27:1527-31.
32. Suguro T, Watanabe T, Ban Y, Kodate S, Misaki A, Hirano T, Miyazaki A, Adachi M. Increased human urotensin II levels are correlated with carotid atherosclerosis in essential hypertension. Am J Hypertens 2007, 20:211-7.
33. Totsune K, Takahashi K, Arihara Z, Sone M, Satoh F, Ito S, Kimura Y, Sasano H, Murakami O. Role of urotensin II in patients on dialysis. Lancet 2001, 358:810-1.
34. Totsune K, Takahashi K, Arihara Z, Sone M, Ito S, Murakami O. Increased plasma urotensin II levels in patients with diabetes mellitus. Clin Sci (Lond) 2003, 104:1-5.
35. Do-Rego JC, Chatenet D, Orta MH, Naudin B, Le Cudennec C, Leprince J, Scalbert E, Vaudry H, Costentin J. Behavioral effects of urotensin-II centrally administered in mice. Psychopharmacology 2005, 183:103-17.
36. Cirino G, Sorrentino R, di Villa Bianca R, Popolo A, Palmieri A, Imbimbo C, Fusco F, Longo N, Tajana G, Ignarro LJ, Mirone V. Involvement of beta 3-adrenergic receptor activation via cyclic GMP- but not NO-dependent mechanisms in human corpus cavernosum function. Proc Natl Acad Sci 2003, 100:5531-6.
37. Katano Y, Ishihata A, Aita T, Ogaki T, Horie T. Vasodilator effect of urotensin II, one of the most potent vasoconstricting factors, on rat coronary arteries. Eur J Pharmacol 2000, 402:R5-7.
38. Gray GA, Jones MR, Sharif I. Human urotensin II increases coronary perfusion pressure in the isolated rat heart: Potentiation by nitric oxide synthase and cyclooxygenase inhibition. Life Sci 2001, 69:175-80.
39. Ishihata A, Ogaki T, Aita T, Katano Y. Role of prostaglandins in urotensin II-induced vasodilatation in the coronary arteries of aged rats. Eur J Pharmacol 2005, 523:119-26.
40. Gardiner SM, March JE, Kemp PA, Maguire JJ, Kuc RE, Davenport AP, Bennett T. Regional heterogeneity in the haemodynamic responses to urotensin II infusion in relation to UT receptor localisation. Br J Pharmacol 2006, 147:612-21.
41. Douglas SA, Tayara L, Ohlstein EH, Halawa N, Giaid A. Congestive heart failure and expression of myocardial urotensin II. Lancet 2002, 359:1990-7.
42. Kimura Y, Naitou Y, Wanibuchi F, Yamaguchi T. Characterization of intracavernous pressure increase induced by Ym348, a novel 5-HT2C receptor agonist, in anesthetized rats. J Urol 2006, 175:1953-7.
43. Andersson KE. Neurophysiology/pharmacology of erection. Int J Impot Res 2001, 13(3):S8-17. suppl